-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
It is known that the new coronavirus infection may cause respiratory failure and death of patients.
Infection COVID-19 immunization
March 2020, the US Food and Drug Administration Bureau ( the FDA ) issued an emergency use authorization HCQ, the sharp rise in the number of prescriptions and use outside of clinical studies.
Manage FDA
Recently, researchers conducted an investigation aimed at estimating the impact of hydroxychloroquine and chloroquine on the survival of new crown patients from all current published and unpublished randomized clinical trial (RCT) evidence.
In this study, researchers systematically identified unpublished RCTs (ClinicalTrials.
Flow chart for inclusion in randomized clinical trials
Flow chart for inclusion in randomized clinical trialsAll-cause mortality was extracted (publications/preprints) or requested from researchers, and combined with random effects meta-analysis, odds ratios (ORs) with 95% confidence intervals (CIs) for hydroxychloroquine and chloroquine were calculated.
The pre-specified subgroup analysis includes patient settings, diagnosis confirmation, control type, and publication status.
The results of the diagnosis of hydroxychloroquine are based on RECOVERY and WHO SOLIDARITY.
Treatment with hydroxychloroquine was associated with increased mortality, while chloroquine did not show benefit.
Original source:
Original source:Cathrine Axfors et al.
Cathrine Axfors et al.
Leave a message here
